2000
Rapid reconstitution of Epstein-Barr virus-specific T lymphocytes following allogeneic stem cell transplantation.
Marshall N, Howe J, Formica R, Krause D, Wagner J, Berliner N, Crouch J, Pilip I, Cooper D, Blazar B, Seropian S, Pamer E. Rapid reconstitution of Epstein-Barr virus-specific T lymphocytes following allogeneic stem cell transplantation. Blood 2000, 96: 2814-21. PMID: 11023516, DOI: 10.1182/blood.v96.8.2814.h8002814_2814_2821.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntigen PresentationAntigens, ViralBeta 2-MicroglobulinBiopolymersCD8-Positive T-LymphocytesChildEpstein-Barr Virus InfectionsFeasibility StudiesFemaleGraft SurvivalHematologic NeoplasmsHematopoietic Stem Cell TransplantationHerpesvirus 4, HumanHistocompatibility TestingHLA-A2 AntigenHLA-B7 AntigenHLA-B8 AntigenHumansKidney TransplantationLymphoproliferative DisordersMacromolecular SubstancesMaleMiddle AgedTissue DonorsT-Lymphocyte SubsetsTransplantation ConditioningTransplantation, HomologousViral LoadConceptsEBV-specific T cellsStem cell transplantationT cellsAllo-PBSCTEBV peptidesCell transplantationT lymphocytesAllogeneic peripheral blood stem cell transplantationEpstein-Barr virus–specific T lymphocytesHuman leukocyte antigen (HLA) class I tetramersEBV-specific CD8 T cellsPeripheral blood stem cell transplantationSpecific CD8 T lymphocytesUnrelated cord blood transplantationVirus-specific T lymphocytesBlood stem cell transplantationAllogeneic stem cell transplantationCD8 T cell repertoireAllo-PBSCT patientsEBV genome copiesEpstein-Barr viremiaCD8 T lymphocytesClass I tetramersCord blood transplantationPathogen-specific immunity
1999
Use of rituximab and irradiated donor-derived lymphocytes to control Epstein–Barr virus-associated lymphoproliferation in patients undergoing related haplo-identical stem cell transplantation
McGuirk J, Seropian S, Howe G, Smith B, Stoddart L, Cooper D. Use of rituximab and irradiated donor-derived lymphocytes to control Epstein–Barr virus-associated lymphoproliferation in patients undergoing related haplo-identical stem cell transplantation. Bone Marrow Transplantation 1999, 24: 1253-1258. PMID: 10642818, DOI: 10.1038/sj.bmt.1702052.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntibodies, MonoclonalAntibodies, Monoclonal, Murine-DerivedAntigens, ViralAntineoplastic AgentsBlood Component TransfusionBlood DonorsDNA, ViralGraft vs Host DiseaseHematologic NeoplasmsHematopoietic Stem Cell TransplantationHerpesvirus 4, HumanHumansImmunosuppression TherapyLymphocytesLymphoproliferative DisordersMalePolymerase Chain ReactionRituximabConceptsEpstein-Barr virus-associated lymphoproliferative disorderStem cell transplantationEBV DNA titersB cell populationsCell transplantationTherapeutic strategiesEpstein-Barr virus-associated lymphoproliferationHaplo-identical stem cell transplantationEffective alternative therapeutic strategyAllogeneic stem cell transplantationCourses of rituximabDonor-derived lymphocytesPost-transplant immunosuppressionMonoclonal B-cell populationCD20 monoclonal antibodyCell populationsAlternative therapeutic strategiesImmunosuppressive medicationsSevere GVHDHost diseaseLymphocyte infusionPost transplantFatal complicationCurative therapyLymphoproliferative disorders